Compare Crispr Therapeutics AG (CRSP) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Old Dominion Freight Line Inc — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while Old Dominion Freight Line Inc trades at $233 (market cap $47.55B). The key difference: Old Dominion Freight Line Inc is far larger — about 9.6× Crispr Therapeutics AG's market cap, and Old Dominion Freight Line Inc pays a 0.51% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ODFL | |
|---|---|---|
Market Cap | $4.97B | $47.55B |
Sector | Health | Industrials |
52-Week High | $76.78 | $248.73 |
52-Week Low | $44.34 | $126.29 |
Enterprise Value | $3.32B | $47.30B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ODFL trades at $232.9, up 2.32% today, with a bullish technical signal from moving averages and oscillators. The company maintains strong profitability with an 18.46% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights improving LTL freight demand and a disciplined capital allocation strategy.
Outlook remains positive due to operational strength and market share gains, but elevated valuation multiples and competitive pressures from players like Amazon pose risks. The stock's proximity to its consensus price target of $232.20 suggests limited near-term upside, requiring careful monitoring of Q2 2026 earnings due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
